Boston Scientific 8-K 2017
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): April 17, 2017
BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in charter)
Registrant's telephone number, including area code: (508) 683-4000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) On April 17, 2017, Timothy A. Pratt, age 67, Executive Vice President, Chief Administrative Officer, General Counsel and Secretary of Boston Scientific since February 2010, informed the Company that he will retire by the end of 2017. Mr. Pratt joined Boston Scientific in May 2008 as Executive Vice President, General Counsel and Secretary. During the next several months, Mr. Pratt intends to lead the efforts to identify his successor and assist in a seamless transition.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.